Your Health, We Care
Sofosbuvir/Velpatasvir is a fixed-dose combination preparation containing sofosbuvir (an HCV nucleotide analog NS5B polymerase inhibitor) and velpatasvir (an HCV NS5A inhibitor). It is indicated for the treatment of adult and pediatric patients aged 3 years and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection, including: patients without cirrhosis or with compensated cirrhosis; and patients with decompensated cirrhosis, which requires combination use with ribavirin.
FDA，2022.04
It is indicated for the treatment of adult and pediatric patients aged 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection. This includes ···【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：0
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
